Replies to post #126673 on Avid Bioservices Inc (CDMO)

[exwannabe]

...have only one p3 approval for Bavi in NSCLC, probably had the same for breast cancer a couple of years ago.

I suspect it is almost impossible to run a P3 in breast cancer as a whole nowadays. The treatment path is so different based on ER/EGFR/HER2 status that it seams like breaking it out by such is needed,

One might argue that they should have ran something like a P2 in triple negative second line, but they have to chose what they see are the best targets (in terms of getting to market fastest/cheapest.

They do have more data than any of us, so ut is hard to judge them n such.